An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

Steroids

Volumn 76, Issue 8, 2011, Pages 772-776

  Martin, L A ^a   Ghazoui, Z ^a   Weigel, M T ^a   Pancholi, Sunil ^a   Dunbier, A ^a   Johnston, Stephen ^b   Dowsett, M ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitor; Breast cancer; Endocrine resistance; Kinases; Oestrogen receptor

Indexed keywords

AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE;

ADAPTATION; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; ESTROGEN DEFICIENCY; FEMALE; GENE EXPRESSION REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LONG TERM ESTROGEN DEPRIVATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MODELS, BIOLOGICAL; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECURRENCE; TRIAZOLES;

EID: 79958765298     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.035     Document Type: Conference Paper

References (17)

1. Dowsett M, Howell A. Breast cancer: aromatase inhibitors take on tamoxifen. Nat Med 2002;8:1341-4. (Pubitemid 36019409)
2. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet 2005;366(9484):431-3. (Pubitemid 41111681)
3. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.nJ. Natl Cancer Inst 2005;97:1262-71. (Pubitemid 41535367)
4. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
5. Coutts AS, Murphy LC. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 1998;58:4071-4. (Pubitemid 28440557)
6. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10. (Pubitemid 40616372)
7. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, et al. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008;68:4910-8.
8. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333-41. (Pubitemid 35279118)
9. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12. (Pubitemid 37328797)
10. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
11. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68. (Pubitemid 36994549)
12. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-16. (Pubitemid 46224019)
13. Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005;12:1017-36.
14. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 1992;43:155-9.
15. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93(22):1714-23. (Pubitemid 33130260)
16. Sabnis G, Brodie A. Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol 2010 [Epub ahead of print].
17. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.